Goldman Sachs Reinstates Buy on Warner Bros.Discovery, Announces $22 Price Target
Goldman Sachs analyst Brett Feldman reinstates Warner Bros.Discovery (NASDAQ:WBD) with a Buy and announces $22 price target.
JMP Securities Initiates Coverage On Century Casinos with Market Outperform Rating, Announces Price Target of $15
JMP Securities analyst Jordan Bender initiates coverage on Century Casinos (NASDAQ:CNTY) with a Market Outperform rating and announces Price Target of $15.
BTIG Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $80
BTIG analyst Julian Harrison initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Buy rating and announces Price Target of $80.
Piper Sandler Assumes Under Armour at Neutral, Announces Price Target of $10
Piper Sandler analyst Abbie Zvejnieks assumes Under Armour (NYSE:UAA) with a Neutral rating and announces Price Target of $10.
Piper Sandler Assumes Wolverine World Wide at Overweight, Announces Price Target of $30
Piper Sandler analyst Abbie Zvejnieks assumes Wolverine World Wide (NYSE:WWW) with a Overweight rating and announces Price Target of $30.
Piper Sandler Assumes Nike at Neutral, Announces Price Target of $115
Piper Sandler analyst Abbie Zvejnieks assumes Nike (NYSE:NKE) with a Neutral rating and announces Price Target of $115.
Piper Sandler Initiates Coverage On On Holding with Overweight Rating, Announces Price Target of $28
Piper Sandler initiates coverage on On Holding (NYSE:ONON) with a Overweight rating and announces Price Target of $28.
RBC Capital Assumes Boyd Group Services at Outperform, Announces Price Target of C$195
RBC Capital analyst Sabahat Khan assumes Boyd Group Services (TSX:BYD) with a Outperform rating and announces Price Target of C$195.
Stifel Initiates Coverage On Sight Sciences with Hold Rating, Announces Price Target of $10
Stifel analyst Thomas Stephan initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Hold rating and announces Price Target of $10.
Wedbush Initiates Coverage On Vor Biopharma with Outperform Rating, Announces Price Target of $18
Wedbush analyst David Nierengarten initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Outperform rating and announces Price Target of $18.